| 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature. | |
| | |
MedLine Citation:
|
PMID: 21625315 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start. |
| | |
Authors:
|
M Greco; M Criscuolo; L Fianchi; E Fabiani; L Pagano; Mt Voso |
Related Documents
:
|
17878395 - Intramuscular methotrexate-induced aseptic meningitis. 1927255 - Fatal streptococcus suis meningitis in man. 8797445 - Torulopsis pneumonia. a case report and review of the literature. 1315105 - Two cases of neonatal pneumococcal septicemia. 19352655 - High-flexion total knee arthroplasty: a systematic review. 6695165 - Botulism revisited. a case report. |
Publication Detail:
|
Type: Journal Article Date: 2011-03-15 |
Journal Detail:
|
Title: Mediterranean journal of hematology and infectious diseases Volume: 3 ISSN: 2035-3006 ISO Abbreviation: Mediterr J Hematol Infect Dis Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-05-31 Completed Date: 2011-07-14 Revised Date: 2011-07-28 |
Medline Journal Info:
|
Nlm Unique ID: 101530512 Medline TA: Mediterr J Hematol Infect Dis Country: Italy |
Other Details:
|
Languages: eng Pagination: e2011011 Citation Subset: - |
Affiliation:
|
Istituto di Ematologia, Università Cattolica Sacro Cuore, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Severe acute hepatitis B treated with entecavir.
Next Document: Zygomycosis in Immunocompromised non-Haematological Patients.